Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Washington University School of Medicine |
---|---|
Information provided by: | Washington University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00352755 |
This study prospectively evaluates a multidisciplinary approach to patients with intraperitoneal carcinomatosis at Washington University. Patients with peritoneal carcinomatosis or pseudomyxoma peritonei will undergo debulking surgery with peritonectomy and placement of adhesive barrier film followed by repeated delayed intraperitoneal chemotherapy with 5FU with systemic oxaliplatin-based chemotherapy on a biweekly schedule for a total of 9 doses. A retrospective review of patients treated in a similar manner at our institution showed good tolerance and efficacy. This formal Phase II study is planned to determine the safety, toxicities and survival of patients with peritoneal carcinomatosis and pseudomyxoma peritonei treated with this regimen.
Condition | Intervention | Phase |
---|---|---|
Peritoneal Neoplasms |
Procedure: Surgical debulking with peritonectomy Drug: Intraperitoneal 5FU Drug: FOLFOX |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Eligibility Criteria:
United States, Missouri | |
Washington University School of Medicine | |
St. Louis, Missouri, United States, 63110 |
Principal Investigator: | James Fleshman, M.D. | Washington University School of Medicine |
Study ID Numbers: | 06-0312 |
Study First Received: | July 14, 2006 |
Last Updated: | May 22, 2007 |
ClinicalTrials.gov Identifier: | NCT00352755 |
Health Authority: | United States: Institutional Review Board |
Pseudomyxoma peritonei Digestive System Neoplasms Pseudomyxoma Peritonei Leucovorin Gelatinous ascites Abdominal Neoplasms Carcinoma |
Oxaliplatin Digestive System Diseases Fluorouracil Peritoneal Diseases Gastrointestinal Neoplasms Peritoneal Neoplasms Neoplasms, Glandular and Epithelial |
Antimetabolites Neoplasms by Histologic Type Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs |
Immunosuppressive Agents Pharmacologic Actions Neoplasms Neoplasms by Site Therapeutic Uses Neoplasms, Cystic, Mucinous, and Serous |